-
Synthetic Nurr1 Ligands as Novel Neuroprotective Therapeutics to Treat Parkinson’s Disease
… including severe side effects such as involuntary movement (dyskinesia). In this regard, successful identification of …
-
Efficacy and Safety of APL-130277 in People with Parkinson’s Disease who are Apomorphine Naïve
… orthostatic hypotension. There were no adverse events of dyskinesia or local mucosal irritation, and no patients …
-
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics
July 22, 2008
… lessen debilitating side effects of the drug including dyskinesias, the uncontrollable movements that arise with …
-
What We Fund: $8 Million in New Grants for Parkinson's Research
November 27, 2018
… symptoms of Parkinson's, along with medication-induced dyskinesias. At McGill University , scientists are looking …
-
New Parkinson’s DBS Research: Does Not Increase Dementia Risk; May Help Earlier in Disease
July 7, 2020
… experience certain complications (such as “off” time and dyskinesia ). But a new study funded by The Michael J. Fox …
-
Ask the MD: New Parkinson’s Treatment Submitted to FDA for Approval
May 24, 2022
… the infusion site and involuntary, uncontrolled movement (dyskinesia). Another ongoing, open-label Phase III trial is …